🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The #Mycology2025 conversation continues beyond the lecture hall!🧫 Explore research in fungal diagnostics, resistance & clinical innovation at our poster submissions.🚀 Join the discussion & connect with top researchers!🌍Get involved now 👏

If you're at Fungal Update today, make sure you catch the next talk (16:15) about tackling antifungal resistance in CPA, by Dr Chris Kosmidis Mycology Reference Centre Manchester #Mycology2025

Great work, so far the largest series on biologics efficacy in #ABPA specifically. 65% response rate in treatment dependent asthma. National Aspergillosis Centre

Congratulations to our #Mycology2025 FungART & poster presentation winners!👏 FungART: 🏆Lorena Symes 🥈Amie-Ella Griffin Poster Presentations: 🏆Chris Kosmidis 🥈Amie-Ella Griffin THANK YOU to all who participated!🌟

Be Part of Research - We are recruiting in our Trial of Interferon-gamma in chronic pulmonary aspergillosis bepartofresearch.nihr.ac.uk/trial-details/…

TB rates are rising faster than at any other time since 1971. Explore clinical resources to help tackle this issue on the Respiratory Futures website. 👉 brit-thoracic.uk/WorldTBDay2025 #WorldTBDay #RespiratoryCare

New EMBARC registry data published ThoraxBMJ - study from 31 countries Inhaled corticosteroids are used by 52.3% of bronchiectasis patients Outcomes are generally worse among ICS users which may be confounding by indication Eosinophilic patients have lower exacerbations!

We have a number of support channels available to those with aspergillosis and their friends and family. Follow the link below for more information. #IDTwitter #MedEd #MedTwitter #support #aspergillosis bit.ly/3zj0nwF

CPA affects ~3,600 people in the UK. Mortality can reach 40% at 5 years. Current treatment = long-term azoles with limited efficacy + resistance concerns. We urgently need new options. The INCAS Trial explores immune modulation with interferon-gamma. #IDTwitter #LungHealth

Study recruiting now. Respiratory and ID clinicians: if you start patients on azoles for chronic aspergillosis they may be eligible to also receive interferon gamma via our RCT. Our preliminary data shows reduction in flares with IFNg National Aspergillosis Centre

Really happy to help raise awareness about chronic pulmonary aspergillosis with European Lung Foundation CPAnet National Aspergillosis Centre europeanlung.org/en/news-and-bl…

📢 Calling all respiratory & infectious disease clinicians: Have a patient with chronic pulmonary aspergillosis (CPA) starting antifungal therapy? They may be eligible for the INCAS Trial, testing interferon-gamma as an adjunct treatment. 🧪 Learn more: ...

CPA affects ~3,600 people in the UK. Mortality can reach 40% at 5 years. Current treatment = long-term azoles with limited efficacy + resistance concerns. We urgently need new options. The INCAS Trial explores immune modulation with interferon-gamma. #IDTwitter #LungHealth

Don't forget to register and send your abstract bsmm.org/BSMM_2024/bsmm… for #BSMM2025 Norwich City Council Assembly House DEADLINE IS SOON!! on 30th May. JOIN US!

Brazilian TV had a long section about fungal pathogens, AMR and the future risks of fungi🔥thoroughly enjoyed the filming day! Highlighting research from Brazil and how we in the UK collaborate across the globe 🌍 to bring awareness for fungal diseases

Heading to ISHAM meeting! Hope to see many of you there! Looking forward to contributing to sessions on chronic fungal lung disease on Wednesday and serological diagnosis of CPA on Friday. National Aspergillosis Centre

📢 Calling all respiratory & infectious disease clinicians: Have a patient with chronic pulmonary aspergillosis (CPA) starting antifungal therapy? They may be eligible for the INCAS Trial, testing interferon-gamma as an adjunct treatment. 🧪 Learn more: bit.ly/443PQGm

📢 Calling all respiratory & infectious disease clinicians: Have a patient with chronic pulmonary aspergillosis (CPA) starting antifungal therapy? They may be eligible for the INCAS Trial, testing interferon-gamma as an adjunct treatment. 🧪 Learn more: bit.ly/443PQGm

Who's going to #BTSSummer2025 tomorrow? Come and say hi 👋 to the National Aspergillosis Centre team at stand G (turn left just as you enter the exhibition hall) Referrals - remote MDT via Teams - support groups - reference laboratory - specialist nurses, physios, pharmacists